Sunday, May 2, 2010

Gene Therapy targeting 12-Lipoxygenase at Eastern Virginia Medical School's Strelitz Diabetes Center

Studies have shown that deleting the gene that produces 12-LO can stop Type 1 diabetes in mice. Studies of donated human beta cells have allowed the researchers to confirm that the enzyme is the cause of beta cell destruction from inflammation. "We've now confirmed that 12-LO is a relevant target in humans, particularly in the pancreas, and will help lead to new therapies," says the EVMS researchers.

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-1102